title: Use of the UPOINT phenotype system in treating Chinese patients with chronic prostatitis/chronic pelvic pain syndrome: a prospective study.
abstract: The urinary, psychosocial, organ-specific, infection, neurological/systemic and tenderness (UPOINT) phenotype system has been validated to be an effective phenotype system in classifying patients with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) in western populations. To validate the utility of the UPOINT system and evaluate the effect of multimodal therapy based on the UPOINT system in Chinese patients with CP/CPPS, we performed this study. Chinese patients with CP/CPPS were prospectively offered multimodal therapy using the UPOINT system and re-examined after 6 months. A minimum 6-point drop in National Institutes of Health-Chronic Prostatitis Symptoms Index (NIH-CPSI) was set to be the primary endpoint. Finally, 140 patients were enrolled in the study. The percentage of patients with each domain was 59.3%, 45.0%, 49.3%, 22.1%, 37.9%, and 56.4% for the UPOINT, respectively. The number of positive domains significantly correlated with symptom severity, which is measured by total NIH-CPSI scores (r = 0.796, P< 0.001). Symptom duration was associated with a greater number of positive domains (r = 0.589, P< 0.001). With 6 months follow-up at least, 75.0% (105/140) had at least a 6-point improvement in NIH-CPSI after taking the therapy. All NIH-CPSI scores were significantly improved from original ones: pain 10.14 ± 4.26 to 6.60 ± 3.39, urinary 6.29 ± 2.42 to 3.63 ± 1.52, quality of life 6.56 ± 2.44 to 4.06 ± 1.98, and total 22.99 ± 7.28 to 14.29 ± 5.70 (all P< 0.0001). Our study indicates that the UPOINT system is clinically feasible in classifying Chinese patients with CP/CPPS and directing therapy.
authors.forename: Xiao
authors.initials: X
authors.lastname: Guan
authors.forename: Cheng
authors.initials: C
authors.lastname: Zhao
authors.forename: Zhen-Yu
authors.initials: ZY
authors.lastname: Ou
authors.forename: Long
authors.initials: L
authors.lastname: Wang
authors.forename: Feng
authors.initials: F
authors.lastname: Zeng
authors.forename: Lin
authors.initials: L
authors.lastname: Qi
authors.forename: Zheng-Yan
authors.initials: ZY
authors.lastname: Tang
authors.forename: Jin-Geng
authors.initials: JG
authors.lastname: Dun
authors.affiliation: Department of Urology, Xiangya Hospital, Central South University, Changsha 410008, China.
authors.forename: Long-Fei
authors.initials: LF
authors.lastname: Liu
mesh_terms: D000328:Adult; D000368:Aged; D000465:Algorithms; D044466:Asian People; D002681:China; D002908:Chronic Disease; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009422:Nervous System Diseases / Q000145:classification; D010147:Pain Measurement / Q000145:classification; D017699:Pelvic Pain / Q000145:classification* / Q000175:diagnosis / Q000628:therapy*; D010641:Phenotype; D011446:Prospective Studies; D011472:Prostatitis / Q000145:classification* / Q000175:diagnosis / Q000628:therapy*; D011584:Psychology / Q000145:classification; D011788:Quality of Life; D013577:Syndrome; D016896:Treatment Outcome; D014570:Urologic Diseases / Q000145:classification